(Adnkronos) - Merck ha annunciato oggi che l'Agenzia italiana del farmaco ha ammesso alla rimborsabilità tepotinib, un nuovo farmaco per il trattamento dei pazienti adulti affetti da carcinoma polmonare non a piccole cellule (NSCLC) avanzato, con alterazioni genetiche che causano lo skipping dell’esone 14 del fattore di transizione mesenchimale epiteliale (METex14). A margine della conferenza stampa è intervenuto Andrea Paolillo, direttore medico di Merck Italia.
Category
🗞
NewsTranscript
00:00 (upbeat music)
00:02 (speaking in foreign language)
00:08 (speaking in foreign language)
00:12 (speaking in foreign language)
00:16 (speaking in foreign language)
00:21 (speaking in foreign language)
00:25 (speaking in foreign language)
00:29 (speaking in foreign language)
00:33 (speaking in foreign language)
00:37 (speaking in foreign language)
00:41 (speaking in foreign language)
00:44 (speaking in foreign language)
00:48 (speaking in foreign language)
00:52 (speaking in foreign language)
00:56 (speaking in foreign language)
01:00 (speaking in foreign language)
01:04 (speaking in foreign language)
01:08 (speaking in foreign language)
01:12 (speaking in foreign language)
01:17 (speaking in foreign language)
01:20 (speaking in foreign language)
01:24 (speaking in foreign language)
01:28 (speaking in foreign language)
01:32 (speaking in foreign language)
01:36 (speaking in foreign language)
01:40 (speaking in foreign language)
01:44 (speaking in foreign language)
01:48 (speaking in foreign language)
01:52 the growth factor, this is its evolution.